Icon

CRENESSITY (NDA218808)- (25MG,50MG,100MG)

CRINECERFONT NEUROCRINE
25MG,50MG,100MG
No No
2041-Jun-09 2029-Dec-13
None None
None No
CRENESSITY is a corticotropin-releasing factor type 1 receptor antagonist indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).
0 0 0
Total Other Developers None
Drugs with Suitability No
25MG ** ** - - -
50MG ** ** - - -
100MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

GenUs Advanced Search




Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.